
ROCKVILLE, Md., March 21 (UPI) -- U.S. firm Emergent BioSolutions said Wednesday it has filed for U.S. approval to test a new treatment for anthrax.
The company said it is seeking approval from the Food and Drug Administration for Anthrax Immune Globulin, a treatment for patients with symptoms of anthrax disease.
With the FDA's go-ahead, expected in about one month, Emergent said it can begin a one-year clinical trial involving 105 healthy volunteers.
The study "is a significant step as we continue to expand our anthrax biodefense product franchise, which includes BioThrax (Anthrax Vaccine Adsorbed), the only FDA-licensed vaccine against anthrax infection, as well as development programs focused on improvements to BioThrax and an enhanced anthrax vaccine," said Fuad El-Hibri, the firm's chairman and CEO.
|
|
|
|
|
|
| Additional Health News Stories | |
MIAMI, May 27 (UPI) --
Tropical Storm Beryl was expected to make landfall Sunday night on the Southeast Coast of the United States, U.S. forecasters said.
|
WINSTON-SALEM, N.C., May 27 (UPI) --
Bluegrass legend Arthel "Doc" Watson was in critical condition following colon surgery at a hospital in Winston-Salem, N.C., his representative said.
|
ANCHORAGE, Alaska, May 27 (UPI) --
A black bear didn't go over a river but went to the woods after scampering through residential and industrial areas of Anchorage, Alaska, police said.
|
To avoid a meltdown in 2006, Ford Motor Co. mortgaged the farm putting up its assets – including its Blue Oval logo, and F-150 pickup and iconic Mustang trademarks – to secure $23.5 billion in credit.
|
| Stories | Photos | People | Comments |
View Caption